Biomarkers in Pulmonary Hypertension

Alberto Maria Marra, Eduardo Bossone, Andrea Salzano, Roberta D'Assante, Federica Monaco, Francesco Ferrara, Michele Arcopinto, Olga Vriz, Toru Suzuki, Antonio Cittadini

Research output: Contribution to journalReview articlepeer-review


Biomarkers are tools in pulmonary hypertension (PH) management. They may address risk assessment, disease progression, response to medical and surgical therapy, risk of right heart failure, and prognosis. The activation of molecular pathways is the pathophysiological underpinning of the biomarkers assessed in peripheral venous blood. A multiparametric approach, involving different biomarkers, is preferred because it provides relevant clinical information regarding different organs and body systems. This is especially true in the final stages of PH with its comorbidities and different pathophysiological patterns, supporting that PH is a systemic condition rather than an isolated cardiorespiratory illness.

Original languageEnglish
Pages (from-to)393-402
Number of pages10
JournalHeart Failure Clinics
Issue number3
Publication statusPublished - Jul 1 2018


  • Biomarkers
  • Prognosis
  • Pulmonary hypertension
  • Risk stratification

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Biomarkers in Pulmonary Hypertension'. Together they form a unique fingerprint.

Cite this